-
Document de presse | 2022.04.12
HIV: The Antibodies of "Post-treatment Controllers"
A very small percentage of people with HIV-1, known as "post-treatment controllers" (PTCs), are able to control their infection after interrupting all antiretroviral therapy.Understanding the fundamental mechanisms that govern their immune response is essential in order to develop HIV-1 vaccines, novel therapeutic strategies to achieve remission, or both.A recent study investigated the humoral...
-
News | 2022.04.14
Monoclonal antibody SPK001: potent and broad neutralization activity across all SARS-CoV-2 variants of concern
SPK001, the monoclonal antibody developed by SpikImm, a biotech company founded by the Institut Pasteur and Truffle Capital, has demonstrated a potent and broad neutralization activity across all SARS-CoV-2 variants of concern, including omicron (BA.1 and BA.2). Originally developed in the Humoral Immunology lab headed by Dr Hugo Mouquet at the Institut Pasteur (joint research unit Inserm),...
-
Document de presse | 2022.04.14
Decoding a direct dialog between the gut microbiota and the brain
Gut microbiota by-products circulate in the bloodstream, regulating host physiological processes including immunity, metabolism and brain functions. Scientists from the Institut Pasteur (a partner research organization of Université Paris Cité), Inserm and the CNRS have discovered that hypothalamic neurons in an animal model directly detect variations in bacterial activity and adapt appetite and...
-
Document de presse | 2022.04.14
How bacteria evade bacteriophages in vivo
Phage therapy, which uses viruses known as bacteriophages to treat bacterial infections, is a long-standing medical procedure whose mechanisms of action are still poorly understood. Scientists from the Institut Pasteur and CNRS have demonstrated in vivo in a murine model that bacteria are capable of regulating their gene expression to evade the numerous bacteriophages present in the gut...
-
Document de presse | 2022.05.04
HIV: bestowing CD8+ T cells with properties observed in natural controllers
HIV controllers are rare individuals able to control infection naturally without treatment. CD8+ T immune cells play a critical role for these individuals, suppressing viral load in the long term even without antiretroviral therapy. Scientists at the Institut Pasteur are examining key characteristics of these controllers' CD8+ T cells, with a view to replicating them in other individuals who are...
-
Document de presse | 2022.05.03
Development of an ensemble model to anticipate short-term COVID-19 hospital demand
For the past two years, the COVID-19 pandemic has exerted pressure on the hospital system, with consequences for patients' care pathways. To support hospital planning strategies, it is important to anticipate COVID-19 health care demand and to continue to improve predictive models.In this study published in the journal PNAS, scientists from the Mathematical Modeling of Infectious Diseases Unit at...
-
Document de presse | 2022.05.11
Hepatitis: 3D structure determination of the ‘gateway’ to the liver
Scientists from CNRS, the Institut Pasteur (France), the Vlaams Instituut voor Biotechnologie and the Vrije Universiteit Brussel (Belgium) have published a ground-breaking study of the structure and function of a central protein in the liver: NTCP, a cellular-entry pathway for bile salts, but also for certain hepatitis viruses. Published in the journal Nature, these results reveal the 3D...
-
News | 2022.05.12
SAVE THE DATE : Pasteur Innov’day - First edition July 7th, 2022!
Fundamentally applied!From basic research to product: the innovation potential of the Institut Pasteur’s continuum Come and meet our researchers to discover some of our emblematic innovations. Integrating complementary expertise from technology platforms and research laboratories, these successes are the result of collaborations involving different teams.Are you a small or medium-sized...
-
News | 2022.05.12
SARS-CoV 2: A booster with a "Lenti-COVID" vaccine candidate induces protective immunity in the respiratory mucosa in a preclinical model
Scientist at the Institut Pasteur- TheraVectys Joint Laboratory have demonstrated the efficacy of their lentiviral candidate vaccine “Lenti-COVID”, administered as an intranasal booster dose six months after primary vaccination with a messenger RNA vaccine, in a pre-clinical model. This intranasal booster induces protective immunity in the respiratory mucosa. These results pave the way for...
-
News | 2022.05.16
mRNA Access: researchers of the Institut Pasteur can benefit from Moderna's mRNA platform for global health
The Institut Pasteur and Moderna have signed a Master Material Transfer Agreement (MMTA) to enable researchers of the Institut Pasteur to have access to Moderna's preclinical manufacturing capabilities and its research and development expertise. The objective is to jointly explore the possibility of mRNA to tackle the world's greatest global public health threats. Institut Pasteur...
